Are you looking for high quality and fully functional humanized recombinant nanobodies that recognize native antigens? We have developed a state-of-the-art Phage Display antibody selection technology to meet your needs.
- Basic research: protein detection, quantification and co-crystallisation
- Diagnosis: Detection of bacteria, viruses and other micro-organisms in biological samples. Immune response measurement (assessment of antibody concentration)
Key benefits of our antibody selection technology
- Nanobodies (smaller, single-domain antibodies) binding native proteins
- Conformational antibodies
- Antibodies working in ELISA & IF
- Several epitopes accessible; Several nanobodies obtained for a given antigen
- Cost-effective production of nanobodies
- No variability from batch to batch
- Versatile tool to use in a vast array of experiments thanks to the possible fusion with Fc fragments from human, mouse or rabbit (see Minibody Cloning & Production)
How does our phage display antibody selection technology work?
Hybrigenics Phage Display antibody selection in an homogenous format is very stringent and uses optimal native antigens without direct adsorption on beads. The hs2dAb library coding 3.109 VHH nanobodies is presented at the phage surface and incubated with the antigen. After a washing step and the elution of selected nanobodies recognizing the antigen, their enrichment is measured. 3 to 4 rounds of antibody selection are performed. Selected nanobodies are validated with our special non-adsorbed Phage ELISA. The principle of the Antibody Phage Display technology is described with more details here.
- 100 µg of purified antigen. If you have less material contact us.
- Full report containing the selection process description and the Phage ELISA data
- Sequences and cDNA clones of up to 10 ELISA-validated nanobodies in the pHEN2 vector (His and myc fusion, expression in E.coli supernatant)